Abstract-Renin-angiotensin systems may mediate cardiovascular disease pathogenesis through a balance of actions of angiotensin II on (potentially proatherogenic) constitutive type 1 (AT 1 R) and (potentially antiatherogenic) inducible type 2 (AT 2 R) receptors. We explored such potential roles in a prospective candidate gene association study. Cardiovascular end points (fatal, nonfatal, and silent myocardial infarction and coronary artery bypass surgery/angioplasty) were documented among 2579 healthy UK men (mean age, 56.1Ϯ3.5 years; median follow-up, 10.1 years) genotyped for the AT 1 R1166AϾC and the X chromosome located AT 2 R1675AϾG and 3123CϾA polymorphisms. Baseline characteristics, including blood pressure, were independent of genotype. The AT 1 R1166CC genotype was associated with relative cardiovascular risk (hazard ratio, 1.65 [1.05 to 2.59]; Pϭ0.03) independent of blood pressure. Systolic blood pressure was associated with risk (Pϭ0.0005), but this association was restricted to AT 2 R1675A allele carriers (PϽ0.00001), with G allele carriers protected from the risk associated with blood pressure (Pϭ0.18). Hypertensive carriers with the AT 2 R1675A/3123A haplotype were at most risk, with 37.5% having an event. This is the first study to demonstrate an association of AT 2 R genotype with coronary risk, an effect that was confined to hypertensive subjects and supports the concept that the inducible AT 2 R is protective. Conversely, the AT 1 R1166CC genotype was associated with cardiovascular risk irrespective of blood pressure. These data are important to our understanding of the divergent role of angiotensin II acting at its receptor subtypes and coronary disease pathogenesis and for the development of future cardiovascular therapies. Coronary vascular ACE drives Ang II synthesis, whose action on local AT 1 and inducible AT 2 receptors (AT 2 R) 2,3 may contribute to coronary heart disease (CHD) pathogenesis: AT 1 R activation causes vascular smooth muscle cell hypertrophy, extracellular matrix production, and local inflammation, driving atherogenesis and plaque rupture, 4 whereas AT 2 R agonism inhibits vascular cell proliferation 5 and may be antiatherogenic. 6 The balance between AT 1 R and AT 2 R activation may therefore influence CHD risk. However, this remains difficult to explore, and supportive data are sparse. Studies involving selective AT 1 R antagonism are perhaps less informative than they might at first appear: although lowering CHD risk more than equihypotensive ␤-blockade, 7 this may be partly mediated through AT 2 R agonism-loss of negative feedback raising Ang II levels and hence binding to the vacant AT 2 R. 8
A s a component of the endocrine renin-angiotensin system (RAS), ACE cleaves angiotensin (Ang) I to yield Ang II. Agonism at the AT 1 receptor (AT 1 R) raises blood pressure (BP) through vasoconstriction and aldosterone action. Meanwhile, local tissue RAS serve different roles. 1 Coronary vascular ACE drives Ang II synthesis, whose action on local AT 1 and inducible AT 2 receptors (AT 2 R) 2,3 may contribute to coronary heart disease (CHD) pathogenesis: AT 1 R activation causes vascular smooth muscle cell hypertrophy, extracellular matrix production, and local inflammation, driving atherogenesis and plaque rupture, 4 whereas AT 2 R agonism inhibits vascular cell proliferation 5 and may be antiatherogenic. 6 The balance between AT 1 R and AT 2 R activation may therefore influence CHD risk. However, this remains difficult to explore, and supportive data are sparse. Studies involving selective AT 1 R antagonism are perhaps less informative than they might at first appear: although lowering CHD risk more than equihypotensive ␤-blockade, 7 this may be partly mediated through AT 2 R agonism-loss of negative feedback raising Ang II levels and hence binding to the vacant AT 2 R. 8 Could there be a role for both the AT 1 R and AT 2 R in the development of CHD? Genetic studies may provide insight. A polymorphism of the AT 1 R gene exists at position 1166, where the C (rather than A) allele is associated with increased Ang II responsiveness. 9 Meanwhile, the A (rather than G) allele at position 1675 of the X-chromosomal AT 2 R gene is associated with a greater left ventricular hypertrophic (LVH) response 10 and the A (rather than C) allele at position 3123 with greater LVH in hypertrophic cardiomyopathy. 11 The AT 1 R 1166C allele may be similarly associated with LVH. 12 The putative association of the AT 1 R 1166C allele with CHD 13, 14 is disputed, 15, 16 whereas no studies have yet addressed the association of AT 2 R-genotype with CHD risk. Furthermore, given the reported associations of the AT 1 R and AT 2 R with a greater hypertensive LVH response, which itself represents an independent risk factor for CHD, 17 it seems likely that polymorphic variation in the AT 1 R and AT 2 R genes may influence the CHD risk associated with hypertension. We therefore sought to clarify these issues through a prospective gene association study.
Methods
Institutional ethics committee approval was granted, and all subjects gave written informed consent.
Study Sample
Subjects were drawn from the Second Northwick Park Heart Study (NPHSII), detailed elsewhere. 18 In brief, NPHSII is a prospective study of 3012 unrelated middle-aged white men (meanϮSD age, 56.1Ϯ3.5 years) from 9 UK general practices. Those with a history of unstable angina, stroke, or electrocardiographic evidence of previous myocardial infarction (MI) were excluded; 1.1% (34/3012) of individuals were lost to follow-up. At entry, systolic and diastolic (Korotkoff V) blood pressures (SBP and DBP, respectively) were measured with a random zero mercury sphygmomanometer after the subject had been seated for 5 minutes. The mean of 2 readings was recorded. At trial inception, systolic and diastolic hypertension were defined as SBP Ն160 mm Hg and DBP Ն95 mm Hg, respectively. 19 Baseline demographics and conventional risk factors for CHD were documented. CHD events were defined as sudden cardiac death or symptomatic MI (based on history, electrocardiography, cardiac enzymes, and pathology: events classified by World Health Organization criteria 20 ), silent MI, or coronary revascularization (surgical or percutaneous). Rare subclinical events were documented though routine electrocardiography at baseline and sixth annual examination. Time to first event was recorded, yielding one event per subject.
Genotyping
Genotypes were determined through the use of polymerase chain reaction amplification of leukocyte DNA, with published primers and conditions used for the AT 1 R1166AϾC 21 and AT 2 R3123CϾA 22 polymorphisms and forward 5ЈCACACTCCTGTAAGAGAAAC-AGCAGCTAAAGAATT-3Ј and reverse 3Ј-CATTCTGCAGCCTG-AATTTTGAAGG-5Ј primers with subsequent EcoR1 digestion for the AT 2 R1675AϾG polymorphism. Products were resolved on a 7.5% polyacrylamide gel, 23 and genotypes were confirmed by two independent technicians blinded to subject outcome, with discrepancies resolved by repeat genotyping. The failure to genotype all individuals for all genotypes relates to quality and quantity of stored DNA and (being random) is not a source of confounding error.
Statistical Analysis
Analysis was performed with the use of Intercooled STATA software (version 7.0, STATA Corp). Subjects with normal blood pressure (nϭ171) but who reported taking antihypertensive medication at recruitment into the trial were excluded before analysis, leaving 2841 eligible subjects. Subjects were followed for a median of 10.1 years. Events consisted of acute (nϭ136) and silent (nϭ18) MI or coronary surgery (nϭ36). The AT 2 R gene is on the X chromosome, so there are no heterozygotes present, and statistical analysis reflects this. Data are expressed as meanϮSD. The effect of genotype on baseline characteristics was tested by 1-way ANOVA. Survival analysis by genotype was performed with the Cox proportional hazards model, and significance was assessed with the use of the likelihood ratio test. All results were exponentiated and presented as hazard ratios (HR) with 95% confidence interval in brackets. Survival probability was examined graphically with the use of Kaplan-Meier plots. Probability values Ͻ0.05 were considered statistically significant. Genotypic association with continuousexpressed BP or presence of hypertension (as defined at the trial inception) was examined. The association between CHD risk and genotype among hypertensive patients was tested, particularly for AT 2 R genotypes, as a threshold phenomenon is predicted in phenotypic differences between variations at any AT 2 R gene locus due to the receptor's inducible nature.
Results
Baseline characteristics of those with at least one genotype available (nϭ2579; 90.8% of eligible subjects) are presented by event status in Table 1 . There were no statistically significant differences in any baseline characteristic between those genotyped and those who were not. No differences in allele, genotype, or haplotype frequencies or in association strength were identified between practices. The type of CHD events did not differ by AT 1 R or AT 2 R genotype ( Table 2) .
AT 1 R1166A>C Polymorphism and CHD Risk
Genotype distribution (AA 1192, AC 882, CC 204) and rare allele frequency (0.28) were similar to those previously reported 9 and consistent with Hardy-Weinberg equilibrium. Baseline characteristics, including blood pressure, in the study group overall were independent of AT 1 R genotype (Table 3) . However, in keeping with previous reports, 24 there was a greater proportion of AT 1 R1166CC carriers with systolic hypertension at baseline (19.6% CC versus 14.6% A allele carriers; Pϭ0.05). CHD event rate was higher among those of CC than AC or AA genotypes (proportion with events, 10.8%, 5.7%, and 8.0%, respectively; Pϭ0.02; HR for CC versus A allele carriers 1.65 [1.05 to 2.59]; Pϭ0.03; Table 2 ). This was confirmed by Kaplan-Meier survival curves ( Figure 1 ), with decreased survival among CC compared with A allele carriers. CHD risk rose exponentially as baseline SBP increased irrespective of genotype (Figures 2a  and 2b ). The increased CHD risk of CC compared with A allele carriers was independent of blood pressure (HR after adjustment for SBP, 1.62 [1.04 to 2.55]; Pϭ0.05). There was no evidence that the risk associated with AT 1 R genotype was different in those with systolic or diastolic hypertension.
AT 2 R1675A>G Genotype
There were 1188 A allele and 1027 G allele carriers. The rare G allele frequency was 0.46 and similar to previous reports. 10 Baseline characteristics, including SBP and DBP, were genotype-independent (Table 4 ). There was also no association with presence of diastolic (Pϭ0.64) or systolic hypertension (Pϭ0.84) at baseline. There was no association between CHD risk and AT 2 R1675AϾG genotype overall (Table 2) Figure 3 ). Among A allele carriers, there was an exponential rise in risk as SBP increased (PϽ0.00001; Figure 2c ). However, G allele carriers were protected from the effects of hypertension, with no association between increasing risk and increasing SBP (Pϭ0.180; Figure 2d ). After a threshold of approximately 150 mm Hg, the risk appeared to increase exponentially only for A allele carriers. The HR for a 1-SD increase in SBP was 1.46 (1.20 to 1.78; Pϭ0.0001) for the A allele but 1.12 (0.91 to 1.38; Pϭ0.30) for the G allele. A similar (but not statistically significant) trend was observed for DBP: the hazard ratio for the A (compared to the G) allele was 1.42 (0.84 to 2.40; Pϭ0.18) for subjects with diastolic hypertension, but only 0.84 (0.59 to 1.20; Pϭ0.33) for those with DBP Ͻ95 mm Hg (P for interaction ϭ0.11).
AT 2 R3123C>A Genotype
Genotype distribution (C 1320 and A 1062) and rare allele frequency (A 0.45) were consistent with previous reports. 11 There was strong evidence of linkage disequilibrium between the AT 2 R1675 and AT 2 R3123 polymorphisms (⌬ϭ0.74, PϽ0.001). Demographic characteristics did not vary by AT 2 R haplotype; 3123A allele carriers were younger then C allele carriers (55.8Ϯ3.4 years versus 56.2Ϯ3.4 years, respectively; Pϭ0.008; Table 3 ). All other baseline characteristics were independent of genotype, and genotype was unrelated to presence of systolic or diastolic hypertension (Pϭ0.30 and Pϭ0.63, respectively). As for the 1675AϾG polymorphism, the 3123CϾA genotype was not associated with risk in the whole cohort, after adjustment for age and practice (A versus C allele HR 1. There was no requirement to adjust for baseline variables having no association with genotype. However, when such complete adjustments were performed, results were unaffected.
Discussion
The association of SBP with CHD risk is shown to be modulated by AT-receptor genotype in this large prospective study: The risk associated with any given BP is genotypedependent, whereas the risk associated with any one allele is influenced by SBP. Thus, AT 1 R 1166CC genotype is associated with elevated CHD risk at all levels of SBP, the gradient of increasing risk with rising SBP being independent of AT 1 R genotype. Conversely, CHD risk is independent of AT 2 R genotype among normotensive individuals, whereas the AT 2 R 1675A allele is associated with excess risk among those with systolic hypertension (as dichotomously defined at trial inception as SBP Ն160 mm Hg). Here, the gradient relating risk to SBP rises exponentially among these individuals, whereas 1675G allele carriers are relatively protected from hypertensive risk. The association of AT 2 R genotype with CHD risk provides the first direct evidence of a role for the AT 2 R in the pathogenesis of CHD. Subgroup analysis suggests that the majority of the risk associated with hypertension in the 1675A allele carriers was confined to those of 1675A/3123A haplotype (found in 5% of UK men). Indeed, 6 of 16 hypertensive men with the 3123A/1675A AT 2 R haplotype had an event over a decade. However, given the relatively small number of hypertensive individuals of this haplotype, the great excess risk associated with this haplotype demands confirmation. This will necessitate the construction of larger, long-term prospective epidemiological genetic studies. Although one of the largest prospective gene association studies published, limited event numbers prevent mathematical study of AT 1 R/AT 2 R genotype interaction. Larger cohorts must thus be sought and observations extended to those of different race and sex.
The observed effects may depend on altered receptor expression. The X-chromosomal AT 2 R gene comprises 3 exons, with exon 3 coding the entire protein sequence. 27 The 1675AϾG polymorphism lies within intron 1 near the region important for gene transcriptional activity, 10 whereas the 3123CϾA polymorphism is located within the 3Ј-untranslated region of exon 3. 22 Intron 1 contains transcriptional enhancers, and in vitro transcription is highest in constructs containing both intron 1 and exon 3. 28 The 1675A allele may thus interfere with enhancer activity, impairing AT 2 R expression and hence increasing cardiovascular risk, and the 3123A allele may also directly reduce transcription. However, both variants may be in allelic association with other unidentified, functional variants within the gene.
The risk of CHD is strongly associated with the development of LVH in response to hypertension. 29 These data would support others 30, 31 in suggesting a causative role for the renin-angiotensin system-and for the AT 1 R 12 and AT 2 R 10,32 specifically-in the common mediation of both CHD and LVH. Both AT 1 R and AT 2 R may have more diverse effects other than on vascular form and function, 4, 6 since Ang II also influences inflammation 25 and coagulation. 26 Further investigation into the (patho)biological actions of angiotensins at the AT 1 R, and particularly AT 2 R, is therefore warranted. AT 2 R1675G allele carriers, (e) AT 2 R3123C allele carriers, and (f) AT 2 R3123A allele carriers. As is to be expected, CHD risk rises steeply as baseline systolic blood pressure rises for AT 1 R genotypes (a, b) and AT 2 R3123 genotypes (e, f). However, this model shows no relation between blood pressure and risk among the 1027 AT 2 R1675G allele carriers (Pϭ0.180) but a highly significant association among the 1168 AT 2 R1675A allele carriers (PϽ10 Ϫ5 ) with a threshold value of Ϸ150 mm Hg for SBP, after which the risk appeared to increase exponentially only for A allele carriers. This is consistent with the notion that AT 2 R offers cardioprotection once a threshold of blood pressure is reached after which it is expressed. These data have substantial implications for our understanding of the pathogenesis of CHD and of the mechanisms of drug action. They also help explain previously paradoxical data. A common polymorphism of the human ACE gene exists in which the presence (Insertion, I allele) rather than the absence (Deletion, D allele) is associated with reduced tissue ACE activity. 33 Pharmacological ACE inhibition substantially reduces coronary event rate in high-risk patients. 31, 34 However, these benefits cannot be ascribed to simple reductions in Ang II activity at the AT 1 R, given that Ang II suppression fails with chronic ACE inhibition 35 (through loss of negative feedback on angiotensinogen 36 and ACE 37 synthesis and conversion of excess Ang I to Ang II through non-ACE pathways 38 ). Rather, an alteration in relative AT 1 R/AT 2 R activity might be responsible: AT 1 R expression increases in response to Ang II 39 and may reduce with ACE inhibition, 40 leading to an altered ratio of AT 1 R/AT 2 R activity. Our data would support a role for such a change in mediating CHD risk reduction. Such an effect might also help explain why the effects of pharmacological ACE inhibition on risk are more marked than that of ACE genotype. 41 Altered AT 1 R:AT 2 R balance may also underlie the greater impact of AT 1 R antagonism than equihypotensive ␤-blockade on coronary event rate in hypertensive patients 7 : Loss of negative feedback causes a rise in Ang II levels and hence binding to the (unprotected) AT 2 R. 8 Furthermore, cross-talk exists between AT 1 and AT 2 receptors, and changes in AT 2 R expression may occur during treatment with AT 1 R antagonists. 42 These results have important implications for geneassociation studies. Allele-associated risk depends on its genetic context and will be modulated by other risk factors such as BP. Failure to take such factors into account may lead to the inappropriate dismissal of important data, accounting perhaps for the mixed reports of association 13, 14 (or lack of it) 15, 16 of AT 1 R genotype with CHD. Indeed, epistatic interaction with ACE genotype, although not detected here (data not shown), has been suggested, 43 whereas we have identified an important AT 2 R haplotype effect. Second, there are lessons for pharmacotherapy. The risk reduction associated with RAS antagonism (whether ACE inhibition or AT 1 R antagonism) may depend on the BP of the individual treated and on the magnitude of the hypotensive response. This will be especially true if the hypertensive phenotype either modulates Ang II receptor expression 44, 45 or is causally associated with differences in expression. 46 The impact of otherwise small falls in BP on CHD risk may thus be amplified when such reductions are associated with ACE inhibition. 31 These issues require investigation in further prospective studies. The impact of ACE inhibition and AT 1 R antagonism on the balance of AT 1 R/AT 2 R activity must also be further explored, such that the advantages of monotherapy/combined therapy in patient subpopulations can be explored.
Finally, a drawback of this study is that specific cardiovascular medication received after enrollment was not documented. However, we feel that this is unlikely to have accounted for the data as presented. First, prescription would have had to have been strongly predicated by genotype to act as a significant confounder, and statistical analysis denies a significant causative role for the alleles in leading to elevated blood pressure. Thus, need for treatment per se (and its impact on outcome) would not have been confounded by any allele association. Second, treatment for hypertensionwhere given-would thus have potentially reduced risk (by blood pressure reduction) in a random way across hypertensive patients, weakening any potential association of allele with risk rather than strengthening it. Third, the use of specific RAS antagonists was uncommon in the time frame of study, especially as their role in primary prevention had yet to be elucidated. It does remain possible that risk reduction associated with such treatment might have been genotypedependent. However, to account for our findings, we would have to suggest almost universal treatment of hypertensive patients and a very strong protective interaction of treatment with the G allele among such patients. Although possible, this seems unlikely. Therefore, it seems implausible that hypotensive therapy would account for our findings. In support, the survival plots diverge by AT 2 R genotype early in the trial. Nonetheless, pharmacogenomic studies are warranted.
Perspectives
Polymorphic variation in the genes for AT 1 and AT 2 receptors influences CHD risk. These data have pharmacotherapeutic and mechanistic implications relating to the treatment of hypertension and of CHD. 
